DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and international markets, beating consensus expectations and pairing this with guidance ...

As of the January 28 closing, DexCom Inc. (NASDAQ:DXCM) had highly bullish sentiment according to consensus. Out of 22 analysts who covered the stock, 18 assigned Buy ratings and 3 gave Hold calls.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

If you are wondering whether DexCom's current share price really reflects what you are getting for your money, you are not alone. The stock last closed at US$73.67, with returns of 4.2% over 7 days, 9 ...

For the first time in a decade, Dexcom has a new chief executive. And, to say Jake Leach has his work cut out for him is ...

DexCom Inc. (NASDAQ:DXCM) is a medical device company that focuses on the design, development, and commercialization of CGM (continuous glucose monitoring) systems in the US and internationally.

At the conference, first-ever accuracy and performance data will be presented for Dexcom's upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making ...

Apple Watch now supports glucose monitoring via CGMs like Dexcom G7, while Apple continues long-term work on non-invasive blood sugar tracking.

Apple Watch now supports glucose monitoring via CGMs like Dexcom G7, while Apple continues long-term work on non-invasive blood sugar tracking.

DexCom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, DexCom has captured an impressive slice of ...

Last year was not a good one for Dexcom ( DXCM +2.51%). The medical device specialist lagged the market, and even with a bit ...

Dexcom reported preliminary, unaudited total revenue of $1.260 billion for the fourth quarter of 2025, an increase of 13% over the fourth quarter of 2024.